The role of everolimus in liver transplantation

References

• StarzlTEMarchioroTLVonkaullaKNHermannGBrittainRSWaddellWRHomotransplantation of the Liver in HumansSurg Gynecol Obstet196311765967614100514
   PubMedGoogle Scholar
• StarzlTEGrothCGBrettschneiderLOrthotopic homotransplantation of the human liverAnn Surg196816833924154877589
   PubMed Web of Science ®Google Scholar
• ZarrinparABusuttilRWLiver transplantation: past, present and futureNat Rev Gastroenterol Hepatol201310743444023752825
   PubMed Web of Science ®Google Scholar
• WiesnerREdwardsEFreemanRModel for end-stage liver disease (MELD) and allocation of donor liversGastroenterology20031241919612512033
   PubMed Web of Science ®Google Scholar
• MazzaferroVRegaliaEDociRLiver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosisN Engl J Med1996334116936998594428
   PubMed Web of Science ®Google Scholar
• ShettyKTimminsKBrensingerCLiver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcomeLiver Transpl200410791191815237377
   PubMed Web of Science ®Google Scholar
• BismuthHHoussinDReduced-sized orthotopic liver graft in hepatic transplantation in childrenSurgery19849533673706367125
   PubMed Web of Science ®Google Scholar
• PichlmayrRRingeBGubernatisGHaussJBunzendahlHTransplantation einer Spenderleber auf zwei Empfänger (Splitting-Transplantation) - eine neue Methode in der Weiterentwicklung der LebersegmenttransplantationLangenbecks Arch Chir1983732127130 German
   Google Scholar
• RaiaSNeryJRMiesSLiver transplantation from live donorsLancet1989286614972570198
   PubMed Web of Science ®Google Scholar
• StrongRWLynchSVOngTHMatsunamiHKoidoYBaldersonGASuccessful liver transplantation from a living donor to her sonN Engl J Med199032221150515072336076
   PubMed Web of Science ®Google Scholar
• CharltonMRBurnsJMPedersenRAWattKDHeimbachJKDierkhisingRAFrequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United StatesGastroenterology201114141249125321726509
   PubMed Web of Science ®Google Scholar
• GordonRDShawBWJrIwatsukiSEsquivelCOStarzlTEIndications for liver transplantation in the cyclosporine eraSurg Clin North Am19866635415563520895
   PubMed Web of Science ®Google Scholar
• StarzlTEDemetrisAJVan ThielDLiver transplantation (2)N Engl J Med198932116109210992677722
   PubMed Web of Science ®Google Scholar
• MorenoRBerenguerMPost-liver transplantation medical complicationsAnn Hepatol200652778516807513
   PubMedGoogle Scholar
• RomeroFARazonableRRInfections in liver transplant recipientsWorld J Hepatol201134839221603030
   PubMedGoogle Scholar
• BerenguerMFerrellLWatsonJHCV-related fibrosis progression following liver transplantation: increase in recent yearsJ Hepatol200032467368410782918
   PubMed Web of Science ®Google Scholar
• CrespoGMarinoZNon-invasive diagnosis of liver fibrosis in the transplant settingDigestive Liver Dis Suppl2011512325
   Google Scholar
• WelkerMWBechsteinWOZeuzemSTrojanJRecurrent hepatocellular carcinoma after liver transplantation – an emerging clinical challengeTranspl Int201326210911822994652
   PubMed Web of Science ®Google Scholar
• FelgaGEvangelistaASSalvalaggioPRHepatocellular carcinoma recurrence among liver transplant recipients within the Milan criteriaTransplant Proc20124482459246123026620
   PubMed Web of Science ®Google Scholar
• Pérez-SaboridoBde los GalanesSJMenéu-DíazJCTumor recurrence after liver transplantation for hepatocellular carcinoma: recurrence pathway and prognostic factorsTransplant Proc20073972304230717889172
   PubMed Web of Science ®Google Scholar
• El-MasryMPuigCASaabSRecurrence of non-viral liver disease after orthotopic liver transplantationLiver Int201131329130221281429
   PubMed Web of Science ®Google Scholar
• GonwaTAMaiMLMeltonLBEnd-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatmentTransplantation200172121934193911773892
   PubMed Web of Science ®Google Scholar
• OjoAOHeldPJPortFKChronic renal failure after transplantation of a nonrenal organN Engl J Med20033491093194012954741
   PubMed Web of Science ®Google Scholar
• HaubenMCyclosporine neurotoxicityPharmacotherapy19961645765838840363
   PubMed Web of Science ®Google Scholar
• GijtenbeekJMvan den BentMJVechtCJCyclosporine neurotoxicity: a reviewJ Neurol1999246533934610399863
   PubMed Web of Science ®Google Scholar
• BechsteinWONeurotoxicity of calcineurin inhibitors: impact and clinical managementTranspl Int200135313326
   Web of Science ®Google Scholar
• GubaMGraebCJauchKWGeisslerEKPro- and anti-cancer effects of immunosuppressive agents used in organ transplantationTransplantation200477121777178215223891
   PubMed Web of Science ®Google Scholar
• TjonASSint NicolaasJKwekkeboomJIncreased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient ageLiver Transpl201016783784620583092
   PubMed Web of Science ®Google Scholar
• WimmerCDAngeleMKSchwarzBImpact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patientsTranspl Int20132610999100623952102
   PubMed Web of Science ®Google Scholar
• SubramanianSTrenceDLImmunosuppressive agents: effects on glucose and lipid metabolismEndocrinol Metab Clin North Am200736489190517983927
   PubMed Web of Science ®Google Scholar
• VincentiFFrimanSScheuermannEDIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) InvestigatorsResults of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimusAm J Transplant2007761506151417359512
   PubMed Web of Science ®Google Scholar
• BianchiGMarchesiniGMarzocchiRPinnaADZoliMMetabolic syndrome in liver transplantation: relation to etiology and immunosuppressionLiver Transpl200814111648165418975273
   PubMed Web of Science ®Google Scholar
• PhamPTPhamPCWilkinsonAHManagement of renal dysfunction in the liver transplant recipientCurr Opin Organ Transplant200914323123919395967
   PubMed Web of Science ®Google Scholar
• SharmaPWelchKEikstadtRMarreroJAFontanaRJLokASRenal outcomes after liver transplantation in the model for end-stage liver disease eraLiver Transpl20091591142114819718633
   PubMed Web of Science ®Google Scholar
• CampbellKMBucuvalasJCRenal function in the long term after pediatric liver transplantation: is there a need for protocol kidney biopsies?Curr Opin Organ Transplant201015560861320733490
   PubMed Web of Science ®Google Scholar
• VinerRMFortonJTColeTJClarkIHNoble-JamiesonGBarnesNDGrowth of long-term survivors of liver transplantationArch Dis Child199980323524010325703
   PubMed Web of Science ®Google Scholar
• BartoshSMThomasSESuttonMMBradyLMWhitingtonPFLinear growth after pediatric liver transplantationJ Pediatr1999135562463110547252
   PubMed Web of Science ®Google Scholar
• CampbellKMYazigiNRyckmanFCHigh prevalence of renal dysfunction in long-term survivors after pediatric liver transplantationJ Pediatr2006148447548016647407
   PubMed Web of Science ®Google Scholar
• VivarelliMCucchettiALa BarbaGLiver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrenceAnn Surg2008248585786218948815
   PubMed Web of Science ®Google Scholar
• VivarelliMCucchettiAPiscagliaFAnalysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppressionLiver Transpl200511549750315838913
   PubMed Web of Science ®Google Scholar
• SolimanTHetzHBurghuberCShort-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantationLiver Transpl20071371039104417600336
   PubMed Web of Science ®Google Scholar
• LiuCLFanSTLoCMInterleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosageLiver Transpl200410672873315162466
   PubMed Web of Science ®Google Scholar
• RamirezCBDoriaCdi FrancescoFIariaMKangYMarinoIRAnti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 monthsJ Surg Res2007138219820417292404
   PubMed Web of Science ®Google Scholar
• TurnerAPKnechtleSJInduction immunosuppression in liver transplantation: a reviewTranspl Int201326767368323651083
   PubMed Web of Science ®Google Scholar
• GrasJMGerkensSBeguinCSteroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 childrenLiver Transpl200814446947718383091
   PubMed Web of Science ®Google Scholar
• SpadaMPetzWBertaniARandomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppressionAm J Transplant2006681913192116771811
   PubMed Web of Science ®Google Scholar
• GanschowRGrabhornESchulzAVon HugoARogiersXBurdelskiMLong-term results of basiliximab induction immunosuppression in pediatric liver transplant recipientsPediatr Transplant20059674174516269045
   PubMed Web of Science ®Google Scholar
• GanschowRBroeringDCStuerenburgIRogiersXHellwegeHHBurdelskiMFirst experience with basiliximab in pediatric liver graft recipientsPediatr Transplant20015535335811560755
   PubMed Web of Science ®Google Scholar
• WiesnerRHFungJJPresent state of immunosuppressive therapy in liver transplant recipientsLiver Transpl201117Suppl 3S1S921850697
   PubMed Web of Science ®Google Scholar
• KimWRSmithJMSkeansMAOPTN/SRTR 2012 Annual Data Report: liverAm J Transplant201414Suppl 1699624373168
   PubMed Web of Science ®Google Scholar
• Neoral^® (cyclosporine) [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2013
   Google Scholar
• Prograf^® (tacrolimus) [package insert]Northbrook, ILAstellas Pharma US Inc2013
   Google Scholar
• CellCept^® (mycophenolate) [package insert]South San Francisco, CAGenentech USA Inc2013
   Google Scholar
• SedraniRCottensSKallenJSchulerWChemical modification of rapamycin: the discovery of SDZ RADTransplant Proc1998305219221949723437
   PubMed Web of Science ®Google Scholar
• SchulerWSedraniRCottensSSDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivoTransplantation199764136429233698
   PubMed Web of Science ®Google Scholar
• KirchnerGIMeier-WiedenbachIMannsMPClinical pharmacokinetics of everolimusClin Pharmacokinet2004432839514748618
   PubMed Web of Science ®Google Scholar
• SalvadoriMBertoniELong-term outcome of everolimus treatment in transplant patientsTranspl Res Risk Manag201137790
   Google Scholar
• Zortress^® (everolimus) [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2013
   Google Scholar
• Rapamune^® (sirolimus) [package insert]New York, NYPfizer, Inc2011
   Google Scholar
• HalloranPFImmunosuppressive drugs for kidney transplantationN Engl J Med2004351262715272915616206
   PubMed Web of Science ®Google Scholar
• WullschlegerSLoewithRHallMNTOR signaling in growth and metabolismCell2006124347148416469695
   PubMed Web of Science ®Google Scholar
• NashanBReview of the proliferation inhibitor everolimusExpert Opin Investig Drugs2002111218451857
   PubMed Web of Science ®Google Scholar
• GubaMvon BreitenbuchPSteinbauerMRapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNat Med20028212813511821896
   PubMed Web of Science ®Google Scholar
• ContrerasAGDormondOEdelbauerMmTOR-understanding the clinical effectsTransplant Proc200840Suppl 10S9S1219100913
   PubMedGoogle Scholar
• CruzadoJMNonimmunosuppressive effects of mammalian target of rapamycin inhibitorsTransplant Rev (Orlando)2008221738118631860
   PubMedGoogle Scholar
• FasoloASessaCTargeting mTOR pathways in human malignanciesCurr Pharm Des201218192766277722475451
   PubMed Web of Science ®Google Scholar
• KawaharaTAsthanaSKnetemanNMm-TOR inhibitors: what role in liver transplantation?J Hepatol20115561441145121781947
   PubMed Web of Science ®Google Scholar
• KovarikJMBeyerDBizotMNJiangQShenoudaMSchmouderRLEffect of multiple-dose erythromycin on everolimus pharmacokineticsEur J Clin Pharmacol2005611353815785960
   PubMed Web of Science ®Google Scholar
• KovarikJMBeyerDBizotMNJiangQAllisonMJSchmouderRLPharmacokinetic interaction between verapamil and everolimus in healthy subjectsBr J Clin Pharmacol200560443443716187976
   PubMed Web of Science ®Google Scholar
• KovarikJMBeyerDBizotMNJiangQShenoudaMSchmouderRLBlood concentrations of everolimus are markedly increased by ketoconazoleJ Clin Pharmacol200545551451815831774
   PubMed Web of Science ®Google Scholar
• KovarikJMBeyerDSchmouderRLEverolimus drug interactions: application of a classification system for clinical decision makingBiopharm Drug Dispos200627942142616955532
   PubMed Web of Science ®Google Scholar
• SchuurmanHJCottensSFuchsSSDZ RAD, a new rapamycin derivative: synergism with cyclosporineTransplantation199764132359233697
   PubMed Web of Science ®Google Scholar
• KovarikJMCurtisJJHricikDEPescovitzMDScantleburyVVasquezADifferential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimusTransplant Proc200638103456345817175302
   PubMed Web of Science ®Google Scholar
• De SimonePMetselaarHJFischerLConversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trialLiver Transpl200915101262126919790150
   PubMed Web of Science ®Google Scholar
• De SimonePCarraiPPrecisiAConversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal functionTranspl Int200922327928619054383
   PubMed Web of Science ®Google Scholar
• De SimonePNevensFDe CarlisLH2304 Study GroupEverolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trialAm J Transplant201212113008302022882750
   PubMed Web of Science ®Google Scholar
• SalibaFDe SimonePNevensFH2304 Study GroupRenal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter studyAm J Transplant20131371734174523714399
   PubMed Web of Science ®Google Scholar
• MasettiMMontaltiRRompianesiGEarly withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal functionAm J Transplant201010102252226220486905
   PubMed Web of Science ®Google Scholar
• FischerLKlempnauerJBeckebaumSA randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation – PROTECTAm J Transplant20121271855186522494671
   PubMed Web of Science ®Google Scholar
• LevyGSchmidliHPunchJSafety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month resultsLiver Transpl200612111640164816598777
   PubMed Web of Science ®Google Scholar
• LevyGAGrantDParadisKCampestriniJSmithTKovarikJMPharmacokinetics and tolerability of 40-0-[2-hydroxyethyl] rapamycin in de novo liver transplant recipientsTransplantation200171116016311211186
   PubMed Web of Science ®Google Scholar
• SalibaFDharancySLorhoRConversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysisLiver Transpl201117890591321384525
   PubMed Web of Science ®Google Scholar
• LeveyASBoschJPLewisJBA more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study GroupAnn Intern Med1999130646147010075613
   PubMed Web of Science ®Google Scholar
• GonwaTAJenningsLMaiMLEstimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equationsLiver Transpl200410230130914762871
   PubMed Web of Science ®Google Scholar
• LetavernierELegendreCmToR inhibitors-induced proteinuria: mechanisms, significance, and managementTransplant Rev (Orlando)200822212513018631865
   PubMedGoogle Scholar
• PengelLHLiuLQMorrisPJDo wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trialsTranspl Int201124121216123021955006
   PubMed Web of Science ®Google Scholar
• WillemsMCHendriksTde ManBMLommeRMvan der VlietJAEverolimus-induced loss of wound strength can be prevented by a short postoperative delay in its administrationWound Repair Regen201119668068622092838
   PubMed Web of Science ®Google Scholar
• NealDATomBDLuanJIs there disparity between risk and incidence of cardiovascular disease after liver transplant?Transplantation2004771939914724441
   PubMed Web of Science ®Google Scholar
• KuoHTSampaioMSYeXReddyPMartinPBunnapradistSRisk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing databaseTransplantation20108991134114020386364
   PubMed Web of Science ®Google Scholar
• IshakKBaptistaABianchiLHistological grading and staging of chronic hepatitisJ Hepatol19952266966997560864
   PubMed Web of Science ®Google Scholar
• SalibaFBrownRSMetselaarHJEverolimus based immunosuppression in hepatitis C virus positive de novo liver transplant recipients: 24-month results from a randomized controlled trial [abstract]Liver Transpl201319Suppl 1S100
   Google Scholar
• VillamilFGGadanoACZingaleFFibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs calcineurin inhibitorsLiver Int Epub20131215
   Web of Science ®Google Scholar
• GanschowRPapeLSturmEGrowing experience with mTOR inhibitors in pediatric solid organ transplantationPediatr Transplant201317769470624004351
   PubMed Web of Science ®Google Scholar
• Van Damme-LombaertsRWebbNAHoyerPFEverolimus Study GroupSingle-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patientsPediatr Transplant20026214715212000472
   PubMed Web of Science ®Google Scholar
• HoyerPFEttengerRKovarikJMEverolimus Pediatric Study GroupEverolimus in pediatric de nova renal transplant patientsTransplantation200375122082208512829916
   PubMed Web of Science ®Google Scholar
• KovarikJMNoeABerthierSClinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokineticsJ Clin Pharmacol200343214114712616666
   PubMed Web of Science ®Google Scholar
• PapeLLehnerFBlumeCAhlenstielTPediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year dataTransplantation201192665866221804444
   PubMed Web of Science ®Google Scholar
• PapeLAhlenstielTEhrichJHOffnerGReversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine APediatr Transplant200711329129517430485
   PubMed Web of Science ®Google Scholar
• NielsenDBriem-RichterASornsakrinMFischerLNashanBGanschowRThe use of everolimus in pediatric liver transplant recipients: first experience in a single centerPediatr Transplant201115551051421696525
   PubMed Web of Science ®Google Scholar
• AlegreCJiménezCManriqueAEverolimus monotherapy or combined therapy in liver transplantation: indications and resultsTransplant Proc20134551971197423769086
   PubMed Web of Science ®Google Scholar
• MajeedTAWaiCTRajekarHExperience of the transplant team is an important factor for posttransplant survival in patients with hepatocellular carcinoma undergoing living-donor liver transplantationTransplant Proc20084082507250918929781
   PubMed Web of Science ®Google Scholar
• TomeSWellsJTSaidALuceyMRQuality of life after liver transplantation. A systematic reviewJ Hepatol200848456757718279999
   PubMed Web of Science ®Google Scholar
• WiesnerRKlintmalmGMcDiarmidSRapamune Liver Transplant Study GroupSirolimus immunotherapy results in reduced roles of acute rejection in de novo orthotopic liver transplant recipientsAm J Transpl20022464
   Google Scholar
• AsraniSKWiesnerRHTrotterJFDe novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000–2003 phase II prospective randomized trialAm J Transplant201414235636624456026
   PubMed Web of Science ®Google Scholar
• ChinnakotlaSDavisGLVasaniSImpact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantationLiver Transpl200915121834184219938137
   PubMed Web of Science ®Google Scholar
• McKennaGJTrotterJFKlintmalmELimiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppressionAm J Transplant201111112379238721967703
   PubMed Web of Science ®Google Scholar
• ChavaSPSinghBStangouASimultaneous combined liver and kidney transplantation: a single center experienceClin Transplant2010243E62E6820618811
   PubMed Web of Science ®Google Scholar